Skip to content

John Harling

John Harling

Company: GlaxoSmithKline

Job title: Senior Scientific Director of Medicinal Chemistry


I conducted both my B.Sc and Ph.D at Imperial followed by two years as a Postdoctoral Researcher at the University of Texas at Austin. Joined GlaxoSmithKline (then SmithKlineBeecham) as a Medicinal Chemist in 1991. During my >25 years at GSK I have worked in programs spanning Neurosciences, Cardiovascular and Respiratory therapeutic areas. In 2007 I was appointed as a Medicinal Chemistry Department Head in the Respiratory therapeutic area. In 2012 I became involved in the initiation of an exploratory effort to assess the potential of a new protein degradation technology through collaboration with Professor Craig Crews at Yale. My current position is Senior Scientific Director within Medicinal Chemistry at GSK where I have a remit to develop protein degradation capability at GSK.


Panel Discussion 2:00 pm

•What are the similarities and differences between traditional drug discovery and TPD during the pre-clinical discovery efforts and clinical studies? • Knowing what we know now, if you were to build a team and a strategy on TPD discovery and development from scratch, what changes would you make if any? • What are the key…Read more

day: Day Two

Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-Mediated Protein Degradation 2:00 pm

• With a significant proportion of the intracellular proteome likely being amenable to PROTAC-mediated degradation, considerable focus needs to be placed on identifying the best therapeutic opportunities for this technology • This presentation will share some experiences at GSK assessing different targets and the consideration of whether a PROTAC approach represented the modality of choice…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.